Ligand Pharmaceuticals
LGND
242 hedge funds and large institutions have $2.27B invested in Ligand Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 80 increasing their positions, 94 reducing their positions, and 40 closing their positions.
4% more capital invested
Capital invested by funds: $2.19B → $2.27B (+$86.5M)
1.27% less ownership
Funds ownership: 228.92% → 227.65% (-1.3%)
4% less funds holding
Funds holding: 252 → 242 (-10)
15% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 94
23% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 40
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
81% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $173M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.7M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$15.7M |
| 3 |
Goldman Sachs
New York
|
+$15.1M |
| 4 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$13.4M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$23M |
| 2 |
BlackRock
New York
|
-$15.5M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
-$14M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.7M |
| 5 |
Two Sigma Advisers
New York
|
-$10.4M |
LGND Hedge Fund Activity: Q4 2020 in Review
242 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2020, worth a combined $2.27B — up 4% from $2.19B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of LGND and 31 opened new positions — a net loss of 9 holders — while 94 trimmed existing stakes and 80 added.
The largest buyer was State Street, adding an estimated $17.7M. The largest seller was Victory Capital Management, cutting an estimated $23M.
- 242 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2020, down from 252 in Q3 2020.
- Funds reported $2.27B of Ligand Pharmaceuticals stock for Q4 2020, up 4% quarter-over-quarter.
- 31 funds opened new Ligand Pharmaceuticals positions in Q4 2020 and 40 closed out, a net change of -9 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2020 was State Street, an estimated $17.7M added.
- The largest Ligand Pharmaceuticals seller in Q4 2020 was Victory Capital Management, an estimated $23M sold.
Based on aggregated 13F filings for Q4 2020.